Datapoint: Supreme Court Ends Repatha-Praluent Patent Saga

The United States Supreme Court on May 18 ended a long-running patent dispute between Amgen, Sanofi and Regeneron over the drugmakers’ PCSK9 inhibitors. Justices upheld a 2019 lower court ruling, which stated that Amgen could not make patent claims over monoclonal antibodies without more thoroughly describing their molecular structure, a decision that could have wider implications for the pharmaceutical industry as a whole. Praluent and Repatha are both approved to treat three forms of high low-density lipoprotein cholesterol (LDL-C); heterozygous familial hypercholesterolemia (HeFH), atherosclerotic cardiovascular disease (ASCVD), and homozygous familial hypercholesterolemia (HoFH). Under the pharmacy benefit, Repatha SureClick holds covered or better status for 82% of all insured lives, to Praluent Pen’s 71%.

SOURCE: MMIT Analytics, as of 5/22/23

0

0

0 Comments

0

0

• Datapoint